Evidence map›Paper›PMID 42614793›Full record

ArticleACS pharmacology & translational science2026

PhiKan 083 Inhibits MYCN Expression in Liver Cancer Cells Independent of p53 Pathways.

Yali Xu, Hricha Mishra, Masataka Takahashi, Hajime Nishimura, Yusuke Suenaga, Wenkui Yu, Yoshitaka Hippo, Harukazu Suzuki, Xian-Yang Qin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yali XuLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Tsurumi-ku, Yokohama 2300045, Japan.
Hricha MishraLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Tsurumi-ku, Yokohama 2300045, Japan.
Masataka TakahashiLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Tsurumi-ku, Yokohama 2300045, Japan.
Hajime NishimuraLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Tsurumi-ku, Yokohama 2300045, Japan.
Yusuke SuenagaLaboratory of Evolutionary Oncology, Chiba Cancer Center Research Institute, Chuo-ku, Chiba 2608717, Japan.
Wenkui YuDepartment of Intensive Care Unit, The Affiliated Drum Tower Hospital, Medical School of Nanjing University, Gulou, Nanjing 210008, China.ORCID https://orcid.org/0000-0003-4218-0321
Yoshitaka HippoLaboratory of Evolutionary Oncology, Chiba Cancer Center Research Institute, Chuo-ku, Chiba 2608717, Japan.ORCID https://orcid.org/0000-0002-4975-1812
Harukazu SuzukiLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Tsurumi-ku, Yokohama 2300045, Japan.
Xian-Yang QinLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Tsurumi-ku, Yokohama 2300045, Japan.ORCID https://orcid.org/0000-0002-0110-6849

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MYCN is a key oncogenic driver in hepatocellular carcinoma (HCC) and a therapeutic challenge due to the historical undruggability of MYC transcription factors (TFs). Using a high-throughput

Indexed as

liver cancerMYCNp53PhiKan 083transcription

Identifiers

PMID42614793
PMCPMC13482878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.